The association between caesarean section and childhood asthma: an updated systematic review and meta-analysis

Allergy, Asthma & Clinical Immunology

Behzad Darabi, 

Shoboo Rahmati, 

Mohammad Reza HafeziAhmadi, 

Gholamreza Badfar & 

Milad Azami 

Allergy, Asthma & Clinical Immunology volume 15, Article number: 62 (2019) 

• details

Abstract

Background

Investigating the association between caesarean section (SC) and childhood asthma has shown contradictory results in different studies. The present study was conducted to determine the association between SC and childhood asthma.

Material and method

The present study was conducted based on the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. All the steps of the study were conducted independently by two reviewers from the inception until February 1, 2019.

The safety and tolerability profile of bilastine for chronic urticaria in children

• Review
• Open Access
• Clinical and Translational Allergy

• Nikolaos G. Papadopoulos & 
• Torsten Zuberbier 

Clinical and Translational Allergy volume 9, Article number: 55 (2019) 

Abstract

Background

Urticaria is a condition defined by the development of wheals, angioedema or both. It is classified based on its duration as acute (≤ 6 weeks) or chronic (> 6 weeks). Chronic urticaria is less frequent than acute one in children, but it represents a debilitating condition, always needing treatment. Symptoms affect child’s daily activities and disturb sleeping patterns, causing emotional distress and negatively influencing learning and cognition.

Clinical Reflections®: Reflecting on Errors and Missed Opportunities in Chronic Urticaria

FORMAT

Roundtable

TIME TO COMPLETE

45 minutes

RELEASED

February 1, 2019

EXPIRES

January 31, 2020

Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.

START ACTIVITY

MAXIMUM CREDITS

0.75 / AMA PRA Category 1 Credit(s)TM

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis

Key Points

Question  Does the oral Janus kinase 1 selective inhibitor abrocitinib improve atopic dermatitis signs and symptoms in adults with moderate to severe atopic dermatitis at doses that are well tolerated?

Findings  In this randomized, double-blinded, phase 2b clinical trial including 267 participants, the proportion of patients achieving substantial improvement from baseline was significantly greater for those receiving 200 mg and 100 mg of abrocitinib compared with placebo. Dose-related decreases in platelet count were observed for all doses greater than 10 mg, but platelet values trended upward toward baseline after the maximum decrease at week 4 and despite ongoing treatment with abrocitinib; most adverse events were mild and considered unrelated to treatment.

SABA overuse: Understanding the reasons for poor asthma control

Prof. John Haughney

Speaker

Clinical Director of the NHS Clinical Research Facilities, Glasgow

Dr John Haughney is a Clinical Director in clinical R&D and the Clinical Research Facilities in NHS Greater Glasgow & Clyde, Scotland, a part-time general practitioner and hospital respiratory specialist. He holds Fellowships from both the Royal College of General Practitioners and the Royal College of Physicians of Edinburgh.

John is a past-president of the International Primary Care Respiratory Group and a former Chair of the GPIAG (PCRS (UK)). He holds honorary academic positions at both the University of Glasgow and the University of Aberdeen and travels extensively teaching and learning about airways disease.

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis

• Research article
• Open Access
• Open Peer Review

BMC Pulmonary Medicine

• Takanori Numata, 
• Katsutoshi Nakayama, 
• Hirofumi Utsumi, 
• Kenji Kobayashi, 
• Haruhiko Yanagisawa, 
• Mitsuo Hashimoto, 
• Shunsuke Minagawa, 
• Takeo Ishikawa, 
• Hiromichi Hara, 
• Jun Araya & 
• Kazuyoshi Kuwano 

BMC Pulmonary Medicine volume 19, Article number: 176 (2019) | 

Abstract

Background

Several major randomized control studies have demonstrated that mepolizumab, an anti-IL-5 monoclonal antibody, is effective for patients with severe eosinophilic asthma who show exacerbation or require systemic corticosteroid maintenance therapy. However, the predictive factors of the response to mepolizumab other than blood eosinophil count are unclear in clinical practice.

Risk factors for severe systemic sting reactions in wasp (Vespula spp.) and honeybee (Apis mellifera) venom allergic patients

• Clinical and Translational Allergy Research Open Access

• Danielle Fehr, 
• Sara Micaletto, 
• Thomas Moehr & 
• Peter Schmid-Grendelmeier 

Clinical and Translational Allergy volume 9, Article number: 54 (2019) | 

Abstract

Frequency of grades according to each insect

Background

Hymenoptera stings are a major cause of anaphylaxis. Various risk factors are discussed in literature. This study aims to investigate potential risk factors for severe sting reactions in wasp (Vespula spp.) and honeybee (Apis mellifera) venom allergic patients and analyses the correlation between diagnostic test results and the severity of the allergic reaction.

Clinically relevant effect of rupatadine 20 mg and 10 mg in seasonal allergic rhinitis: a pooled responder analysis

• Clinical and Translational Allergy
• Research
• Open Access
• 
  

• Joaquim Mullol, 
• Iñaki Izquierdo, 
• Kimihiro Okubo, 
• Giorgio Walter Canonica, 
• Jean Bousquet & 
• Antonio Valero 

Clinical and Translational Allergy volume 9, Article number: 50 (2019) 

Abstract

Background

Different clinical trials showed the superior efficacy of rupatadine compared to placebo at improving seasonal allergic rhinitis (SAR) symptoms, but no study has assessed if the response promoted is clinically meaningful.